Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.51 |
| ▸ | CDK2 | P24941 | 6/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289097 | 0.95 | GSK3B (0.59) | GSK3BCCNE1CDK2NAMPTCHEK1 | |
| SCHEMBL14307166 | 0.94 | GSK3B (0.56) | GSK3BCCNE1CDK2NAMPTCHEK1 | |
| SCHEMBL12954475 | 0.93 | GSK3B (0.58) | GSK3BNAMPTCHEK1 | |
| SCHEMBL12954082 | 0.92 | GSK3B (0.53) | GSK3BCCNE1CDK2NAMPTCHEK1 | |
| SCHEMBL14545841 | 0.92 | GSK3B (0.56) | GSK3BNAMPTCHEK1 | |
| SCHEMBL13289378 | 0.91 | GSK3B (0.53) | GSK3BCCNE1CDK2NAMPTCHEK1 | |
| SCHEMBL13120561 | 0.91 | GSK3B (0.70) | GSK3BCCNE1CDK2 | |
| SCHEMBL14607249 | 0.90 | GSK3B (0.55) | GSK3BCDK2NAMPTCHEK1 | |
| SCHEMBL14418840 | 0.89 | GSK3B (0.53) | GSK3BCDK2NAMPTCHEK1 | |
| SCHEMBL13289101 | 0.88 | GSK3B (0.56) | GSK3BCCNE1CDK2NAMPTCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | GSK3B 749/4885CCNE1 37/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.